麦田稻草人
Lv7
5005 积分
2021-05-28 加入
-
De-escalated neoadjuvant pertuzumab plus trastuzumab therapy with or without weekly paclitaxel in HER2-positive, hormone receptor-negative, early breast cancer (WSG-ADAPT-HER2+/HR-): survival outcomes from a multicentre, open-label, randomised, phase 2 trial
9天前
已完结
-
Eliminating breast surgery for invasive breast cancer in exceptional responders to neoadjuvant systemic therapy: a multicentre, single-arm, phase 2 trial
9天前
已完结
-
Eliminating breast surgery for invasive breast cancer in exceptional responders to neoadjuvant systemic therapy: a multicentre, single-arm, phase 2 trial
9天前
已完结
-
Preoperative single-dose camrelizumab and/or microwave ablation in women with early-stage breast cancer: A window-of-opportunity trial
22天前
已完结
-
Patient Satisfaction Increases with Nipple Reconstruction following Autologous Breast Reconstruction
1个月前
已完结
-
Overview of authorized drug products for subcutaneous administration: Pharmaceutical, therapeutic, and physicochemical properties
1个月前
已完结
-
The key aroma components of steamed green tea decoded by sensomics and their change under different withering degree
1个月前
已完结
-
3-year invasive disease-free survival with chemotherapy de-escalation using an 18F-FDG-PET-based, pathological complete response-adapted strategy in HER2-positive early breast cancer (PHERGain): a randomised, open-label, phase 2 trial
1个月前
已完结
-
Clinical, Epidemiologic, and Pathologic Significance of ERBB2-Low Expression in Breast Cancer
2个月前
已完结
-
Abstract P6-10-03: Datopotamab Deruxtecan (Dato-DXd) in Advanced Triple-Negative Breast Cancer (TNBC): Updated Results From the Phase 1 TROPION-PanTumor01 Study
2个月前
已完结